TorreyPines Therapeutics' CEO Neil Kurtz, M.D., to Moderate Discussion Following Presentations by Tony Yaksh, Ph.D.; Jerome Goldstein, M.D.; and
Alan J. Tuchman, M.D.
LA JOLLA, Calif., June 20 /PRNewswire/ -- A Webinar hosted by TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) at 11 a.m. EDT on June 25 will bring together industry experts to discuss the opportunity of treating chronic pain, migraine and muscle spasticity through the inhibition of the neurotransmitter glutamate.
The company's President and Chief Executive Officer, Neil Kurtz, M.D., will moderate a discussion following brief presentations by:
-- Tony Yaksh, Ph.D., Professor and Vice Chairman for Research, Department of Anesthesiology, and Professor of Pharmacology at the University of California, San Diego
Dr. Yaksh will present information about glutamate receptors in the central nervous system as a target for chronic pain therapy. The focus of his research is the physiology and pharmacology of pain processing. A member of numerous professional societies, Dr. Yaksh has been a consultant to the U.S. Food and Drug Administration and serves on the editorial boards of several journals. He has received many awards, including the FWL Kerr Award from the American Pain Society and the American Society of Anesthesiology Award for Excellence in Research.
-- Jerome Goldstein, M.D., Director of the San Francisco Headache Clinic and a board-certified neurologist who focuses on the diagnosis, treatment, prevention and cure of headache
Dr. Goldstein will present information about glutamate receptors in the
brain as a target for acute and prophylactic migraine therapy. He is a
member of the American Headache Society, The
'/>"/>
| SOURCE TorreyPines Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved |